United
States Fecal Transplants Market is anticipated to grow significantly in the
projected period. United States Fecal Transplants Market is driven by the rising prevalence of gastrointestinal
disorders. Additionally, growing awareness related to microbiome-based
treatments for different diseases is further expected to support the growth of
United States Fecal Transplants Market. According to clinicaltrials.gov,
there are around 216 studies going on in the United States which are in
different phases of developments, related to microbiome-based treatments.
Fecal transplants, also known as fecal microbiota
transplantation (FMT), have emerged as a groundbreaking medical procedure in
recent years. This innovative treatment involves transferring healthy
microbiota from a donor's fecal matter into the gastrointestinal tract of a
patient, aiming to restore the balance of gut bacteria and combat various
digestive disorders. In the United States, the fecal transplants market has
witnessed significant growth, with an increasing number of patients seeking this
alternative therapy to alleviate their gastrointestinal conditions. Digestive
disorders such as Clostridium difficile infection (CDI), inflammatory bowel
disease (IBD), irritable bowel syndrome (IBS), and others have become
increasingly prevalent in the United States. Fecal transplants offer a
promising solution, as they have shown remarkable success rates in treating Clostridium
difficile infection, which is notoriously challenging to manage with
conventional therapies, hence augmenting the growth of the United
States Fecal Transplants Market.
Further, as the medical community and the general public gain a deeper
understanding of the crucial role gut microbiota plays in overall health, the
acceptance and adoption of fecal transplants as a viable treatment option have
increased. Fecal Transplants shows
promise in managing inflammatory bowel disease, which includes conditions like
Crohn's disease and ulcerative colitis, leading to the expansion of United
States Fecal Transplants Market.
Research suggests that restoring a healthy gut
microbiome through fecal transplants may alleviate symptoms and reduce
inflammation in inflammatory bowel disease patients. Although fecal transplants
for IBS are still in the early stages of research, initial studies have shown
potential benefits. FMT aims to restore gut microbial diversity, leading to
improved gut function and reduced irritable bowel syndrome symptoms. The rising
awareness among patients and healthcare professionals has positively impacted
the market growth. In addition, regulatory bodies, such as the U.S. Food and
Drug Administration (FDA), have recognized the potential benefits of fecal
transplants. This regulatory support has encouraged research and development in
the field and facilitated market growth. Additionally, increasing spending to
support the development is further expected to support the market growth. As
per the American Medical Association (AMA), In 2021, the United States'
health spending increased by 2.7% to USD4.3 trillion or USD12,914 per capita.
Ongoing research into the human gut microbiome continues to unravel its
complexities, leading to a deeper understanding of its role in various
diseases. These advancements may pave the way for personalized fecal
transplants and the development of targeted therapies that leverage specific
microbial strains, which is expected to propel the growth of the United
States Fecal Transplants Market.
Download Free Sample Report
Increasing
Prevalence of Inflammatory Bowel Disease Drives United States Fecal Transplants
Market
Gastrointestinal disorders affect a large number of
individuals, significantly impacting their quality of life and posing a
considerable economic burden on healthcare systems. Conditions such as CDI,
inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), and even
certain metabolic disorders have been linked to an imbalance in gut microbiota.
These disorders often require long-term management and can be challenging to
treat with conventional therapies. Fecal transplants offer a promising solution
by replenishing the gut microbiome with beneficial bacteria, providing a
potential breakthrough in the field of gastroenterology. The increasing
prevalence of inflammatory bowel disease has created a growing demand for
alternative treatment options beyond traditional medications, such as
immunosuppressants and biologics. As per the Crohn’s & Colitis
Foundation of America (CCFA), Inflammatory bowel disease (IBD), which includes,
Crohn’s disease and ulcerative colitis, affect as many as 1.6 million people in
the United States, most of whom are diagnosed before age 35. Fecal
transplants have gained significant attention due to their potential to address
the root cause of inflammatory bowel disease by restoring the balance of gut
microbiota. As a result, the United States fecal transplants market has
experienced substantial growth. Fecal microbiota transplantation has emerged as
a potential game-changer in the field of gastroenterology. The rationale behind
fecal transplants is that the gut microbiota plays a crucial role in maintaining
the overall health of the gastrointestinal system, and an imbalance in the
microbial community can contribute to the development and progression of inflammatory
bowel disease. Moreover, the U.S. Food and Drug Administration (FDA) has
recognized the therapeutic potential of fecal transplants and has provided
guidelines for their use in specific cases, leading to the growth of the United
States Fecal Transplants Market. In
2013, the FDA classified FMT as an investigational new drug (IND), allowing healthcare
professionals to conduct clinical trials and use the procedure under specific
conditions.
Increasing Research and Development Drives United
States Fecal Transplants Market
United
States has emerged as a leading hub for fecal transplant research and
development. Extensive R&D efforts have been directed towards understanding
the mechanisms of the human microbiome and the therapeutic potential of fecal
transplants. The rise in funding for clinical trials, academic research, and
private ventures has accelerated progress in this field. Researchers are
exploring the potential of fecal transplants for a broad range of indications
beyond CDI. Preliminary studies have indicated positive outcomes in IBD, IBS, metabolic
disorders like obesity and diabetes, and even mental health conditions such as
depression and anxiety. As these conditions continue to pose significant
challenges to public health, the demand for innovative treatments like fecal
transplants is increasing. Moreover, advancements in the field of biotechnology
and the availability of next-generation sequencing technologies have enhanced
researchers' ability to study the gut microbiome in depth. These tools have
allowed for a better understanding of the complex interactions between gut
bacteria and the human body. As a result, scientists can identify specific
bacterial strains or consortia that may have therapeutic potential. These
developments have opened up new avenues for personalized medicine and the
targeted use of fecal transplants, booming the growth of the United States Fecal
Transplants Market. As per the World Bank, Research and development
expenditure in the United States in 2020 was reported as 3.45% of the total
GDP.
Favorable
Regulatory Support and Clinical Guidelines
Recognizing
the potential of fecal transplants, regulatory bodies and professional
societies have taken steps to facilitate their safe and effective
implementation. The U.S. Food and Drug Administration (FDA) has issued guidance
documents outlining regulatory requirements for fecal microbiota
transplantation, ensuring that appropriate standards are met during the
clinical application of this therapy. Additionally, professional organizations,
such as the American Gastroenterological Association (AGA), have developed
clinical guidelines for the use of fecal transplants in specific conditions.
These guidelines provide healthcare providers with evidence-based
recommendations on patient selection, donor screening, and procedural aspects,
further promoting the adoption of fecal transplants as a viable treatment
option, leading to the expansion of the United States Fecal Transplants Market.
Strong
Clinical Pipeline Drives United States Fecal Transplants Market
United
States is witnessing an active and robust clinical pipeline focused on
exploring the efficacy of fecal transplants in various medical conditions.
Academic institutions, research organizations, and pharmaceutical companies are
investing in clinical trials to further understand the therapeutic potential
and optimize the use of Fecal Transplants. These clinical trials are
investigating the use of fecal transplants in treating conditions such as
ulcerative colitis, Crohn's disease, metabolic disorders, liver diseases, and
even mental health disorders. The results from these trials are expected to
provide valuable insights into the safety, efficacy, and long-term outcomes of
fecal transplantation. Successful outcomes from these studies could lead to
expanded indications and FDA approvals, which would significantly contribute to
the growth of the United States Fecal Transplants Market. As per the
research studies, the number of clinical pipelines for gastrointestinal
diseases increased by 33%over the given years in the United States in the year
2019.
Product
Approvals
· In April 2023, US health officials approved
capsules by Seres Therapeutics to fight dangerous gut infections. This is the
first pill made from healthy bacteria found in human waste. Seres Therapeutics
treatment introduces a simplified, rigorously tested version of the stool
sampling techniques that some experts have been using for over ten years.
· In January 2023, A fecal based therapy for
prevention of recurrent Clostridium difficile infection has been approved by
the Food and Drug Administration. The first FDA approved therapy for the
microbiome is a novel biologic called Rebyota.
Market
Segmentation
United States Fecal Transplants Market is segmented
into Procedure, Disease, Company, and Regional Distribution. Based on Procedure,
United States Fecal Transplants market is divided into Fecal
Bacteriotherapy, Fecal Transfusion, Fecal Enema, Human Probiotic Infusion, and
Stool Transplant. Based on Disease, United
States Fecal Transplants market is categorized into Autism, Parkinson's Disease
(PD), Obesity, Diabetes Mellitus, Clostridium Difficile Infection, and Others. Based
on Region, the United States Fecal Transplants market is segmented into the North-East,
Mid-West, West and South.
Company
Profiles
OpenBiome,
Maat Pharma, Finch Therapeutics, Rebiotix, Seres Therapeutics, Vedanta
Bioscience, Rebiotix, Inc, Osel Inc are some of the key players of United States
Fecal Transplants market.
|
Attribute
|
Details
|
|
Base Year
|
2022
|
|
Historic Data
|
2018 – 2021
|
|
Estimated Year
|
2023
|
|
Forecast Period
|
2024 – 2028
|
|
Quantitative Units
|
Revenue in USD Million, and CAGR for 2018-2022 and 2023-2028
|
|
Report coverage
|
Revenue forecast,
volume forecasting, Company shares, competitive landscape, growth factors,
and trends
|
|
Segments covered
|
Procedure
Disease
|
|
Regional scope
|
North-East,
Mid-West, West and South
|
|
Key companies profiled
|
OpenBiome, Maat Pharma, Finch Therapeutics, Rebiotix, Seres
Therapeutics, Vedanta Bioscience, Rebiotix, Inc, Osel Inc
|
|
Customization scope
|
10% free report customization with purchase. Addition
or alteration to country, regional & segment scope.
|
|
Pricing and purchase
options
|
Avail customized
purchase options to meet your exact research needs.
|
|
Delivery Format
|
PDF
and Excel through Email (We can also provide the editable version of the report
in PPT/Word format on special request)
|
Report Scope:
In this report, the United States Fecal Transplants market has
been segmented into the following categories, in addition to the industry trends,
which have also been detailed below:
- United
States Fecal Transplants Market, By Procedure:
- Fecal
Bacteriotherapy
- Fecal Transfusion
- Fecal
Enema
- Human
Probiotic Infusion
- Stool
Transplant
- United
States Fecal Transplants Market, By Disease:
- Colored
- Autism
- Parkinson's
Disease (PD)
- Obesity,
Diabetes Mellitus
- Clostridium
Difficile Infection
- Others
- United
States Fecal Transplants Market, By Region:
- North-East
- Mid-West
- West
- South
Competitive landscape
Company Profiles: Detailed
analysis of the major companies in United States Fecal Transplants market.
Available Customizations:
With the given market data, TechSci
Research offers customizations according to a company’s specific needs. The
following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players
(up to five).
United States Fecal
Transplants Market is an upcoming report to be released soon. If you wish an early
delivery of this report or want to confirm the date of release, please contact
us at [email protected].